Funded Projects

This team will use their Neuroscience:Translate award to develop a large-scale bi-directional neural interface that will restore high-fidelity vision to people blinded by retinal degeneration.

This team will use their Neuroscience:Translate award to employ a novel therapeutic technique to correct pathogenic mutations causing Parkinson’s disease.

This team will use their Neuroscience:Translate award to develop an entirely new class of ischemic stroke treatment device that will lead to improved clot extraction to improve the success of endovascular thrombectomy.

This team will use their Neuroscience:Translate award to develop the first wearable ultrasound (US) device for the treatment of inflammatory diseases, such as Rheumatoid Arthritis (RA) and Inflammatory Bowel Disease.

We propose a new line of research whose goal is to examine the druggability of a protein-protein interface involving ApoE, an apolipoprotein whose gene variants represent the strongest genetic risk factor for AD.

People with Parkinson’s Disease (PD) have different types of bacteria in their guts compared to people without neurological diseases. We will study which gut bacteria for people with PD to gain a better understanding of how gut bacteria contribute to inflammation in the body and in the brain or people with this condition. 

We propose to apply mass spectrometry techniques to measure BHB-Phe and other KD metabolites in children undergoing KD for refractory epilepsy at Stanford. Further, in a mouse model of refractory genetic epilepsy, we will compare targeted BHB-Phe treatment to full KD treatment using transcriptomics, EEG assessment of seizures and cognitive testing.

Why do all our brains mature and age in different ways, leading to different cognitive and behavioral outcomes? We envision a novel method that “copies” the information from the RNAs made by the neurons to sensor RNAs we artificially introduce into live animals. 

In this study, we aim to (i) perform a feasibility study to determine the acceptance and feasibility of performing such recordings in the AN and ARFID eating disorders population and (ii) test the hypothesis that the electrophysiologic monitoring of the brain and stomach is associated with a clinically validated behavioral measure of interoception involving water distention of the stomach.

Developing an automated seizure detection and localization system based on deep neural networks, EEG data, and real-time video with the goal to dramatically increase neurologist diagnostic capabilities while improving quality of care.

This proposal brings together faculty with this diverse expertise to develop the first gold standard test of auditory-vocal affect. Once developed, validated, and normed, we will deploy this test in the clinical context of autism to quantify impairments and direct neurobiological investigation.

This team is developing a device that will enable accurate diagnosis of Parkinson’s disease via telemedicine. They initially introduced the technology of Quantitative DigitoGraphy (QDG) using a repetitive alternating finger tapping (RAFT) task on a musical instrument digital interface (MIDI) keyboard and will use Neuroscience: Translate funding for the next stage of device development.

We will comprehensively define the gene network associated with mitochondrial dysfunction in Parkinson's disease using a cutting-edge technology, CRISPR, to understand how these nerve cells die in PD and how we can reverse the cell death to treat the disease.